Lori Goldstein, MD, FASCO
- Request Appointment
- Clinical Locations
- Education, Training & Credentials
- Patient Stories
- Research Profile
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Chief of Breast Medical Oncology
Director, The Naomi and Phil Lippincott Breast Evaluation Center
Deputy Associate Director of Clinical Research
Professor of Medicine, Department of Hematology Oncology
- Systemic chemotherapy, hormonal therapy and biologic therapy for early and advanced stage breast cancer
- Clinical and translational trials in breast cancer
- America’s Top Doctors®, 2012-2016
- Philadelphia Magazine Top Docs, 2009-2016
- Best Doctors in America®, 2013-2015
In addition to my clinical expertise in breast cancer, I am dedicated to breast cancer research. At Fox Chase, I was the first leader of the Breast Cancer Research Program (now the Women's Cancer Research Program). In this program, I work with investigators from basic, clinical, and population science who collaborate in their research of breast cancer prevention, what causes tumors to develop, detection and treatment.
I have devoted my career to translational research, which turns basic research into therapeutic treatment for breast cancer patients. At the same time, my interest in investigational research is to reduce the incidence of breast cancer and improve outcomes.
I am committed to generating a national agenda for breast cancer research and care. Because of this interest along with my experience in research, Fox Chase Cancer Center has chosen me to represent the institution as the Principal Investigator for the Eastern Cooperative Oncology Group (ECOG). ECOG conducts clinical trials in all types of adult cancers and is one of the largest clinical cancer research organizations in the United States. ECOG has appointed me as an active member of their Breast CORE committee and Principal Investigator for the Data Safety and Monitoring Committee.
In addition, I serve as a member of the Breast Cancer Guidelines Committee for the National Comprehensive Cancer Network (NCCN), an alliance of 21 of the world's leading cancer centers, including Fox Chase Cancer Center. In my time here, I have been at the start of some major programs, including my experience as the original Director of the Women’s Cancer Center and one of the establishing members of the Clinical Breast Cancer Survivors Program at Fox Chase Cancer Center. I am also on the Institutional Review Board; Data Safety and Monitoring Committee, Extramural Research Program; Steering Committee of Breast Survivorship Program; Navigation Steering Committee; and the Ambulatory Services Steering Committee. Collapse
- Oncology Fellow, Division of Cancer Treatment and Division of Cancer Biology and Diagnosis, National Cancer Institute, Washington, DC
- Resident, Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MD, State University of New York Upstate College of Medicine, Syracuse, NY, 1982
- American Board of Internal Medicine
- Internal Medicine
- Medical Oncology
- National Comprehensive Cancer Network (NCCN)
- Breast Cancer Panel
- Program Director, Breast Cancer Symposium, Fox Chase Cancer Center
- Course Director, Fox Chase Cancer Center Highlights of SABCS CME Program
- American Association for the Advancement of Science
- American Association of Cancer Research
- American Society of Clinical Oncology
- National Accreditation Program for Breast Cancer Centers
- Women in Cancer Research
Honors & Awards
- America’s Top Doctors®, 2012-2016
- Philadelphia Magazine Top Doctors, 2009-2016
- Best Doctors in America®, 2013-2015
- Susan G. Komen "Light of Life Award,” 2014
In October 2012, Patti and Michael Rose were enjoying parenthood, busy raising seven active children, ranging in ages from 2-18. Most women begin annual mammography at the age of 40. Patti, who was 36, never had a mammogram. After she detected a marble-sized lump in her breast, she scheduled her first mammogram and ultrasound, which was followed with a biopsy. Within five days, Patti learned she had breast cancer.
“Fox Chase Cancer Center is the best – and we’re so fortunate it is right around the corner.”
Laura Marblestone's mother was only 43 when she lost her fight with breast cancer. That's why Laura, a registered nurse and resident of Langhorne, PA, regularly performed breast self-exams. In May 1990, at the age of 40, Laura detected lumps in her left breast. Results from a lumpectomy were benign, but around the same time, she developed a lump under her arm, which her doctor said was a swollen lymph gland, likely related to the surgery. "He told me it was nothing, I didn't have to worry."
In 2002, Shari Lynn's husband, Mark, accepted a new job in another state. Together, Shari and Mark made the decision to move their family from New York to Pennsylvania. Shari was like many other moms in her situation. In preparing for the move, she scheduled routine doctor appointments on Long Island so they would not feel pressured to find new physicians right away.
If you have a question about Fox Chase Cancer Center, ask Robin Luber. She spends every Wednesday volunteering at Fox Chase so you are likely to see her walking the halls helping patients and families or in the Family Surgical Waiting Lounge. She also volunteers in Social Services assisting the social workers with administrative tasks. "I love this job," shared Robin. "I help patients, their families, and the staff. It's very rewarding." And that's coming from a former patient.
- Translational studies in breast cancer
- Development of novel therapeutic strategies in breast cancer
- Molecular targeting of breast cancer
Goldstein, LJ, Gray, R, Badve, S, Childs, BH, Yoshizawa, C, Rosley, S, Shak, S, Baehner, FL, Ravdin PM, Davidson, NE, Sledge, GW, Perez, E, Shulman, LN, Martino, S, Sparano, JA: Prognostic Utility of the 21-Gene Assay in Hormone Receptor Positive Operable Breast Cancer with Classical Prognostic Factors and an Integrator of Classical Clinicopathologic and Treatment Information. JCO, Vol. 26, No. 25, Pg. 4063, September 2, 2008. PubMed
Goldstein, L.J., O’Neill, A., Sparano, J.A., Perez, E.A., Shulman, L.N., Martino, S.,Davidson, N.: Concurrent doxorubicin plus doxetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0-3 positive axillary nodes: results of North American Breast Cancer Intergroup Trial E2197. JCO, Vol. 26, No. 25, Pg. 4092, September 2, 2008. PubMed
Finn, RS, Bengala, C, Strauss, LC, Fairchild, J, Sy, O, Ibrahim, N, Rouche, H, Sparano, J, Goldstein, LJ.: Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. Clin Cancer Res. 2011 Nov 1;17(21):6905-13.
Tevaarwerk AJ, Gray R, Schneider BP, Smith ML, Wagner LI, Fetting J, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in Metastatic Recurrent Breast Cancer after Adjuvant Chemotherapy: Little Evidence for Improvement Over the Past Three Decades. Cancer. 2013 Mar;119(6):1140-8. PMCID: 3593800
Goldstein, LJ, Tosello-Oliveria, C, Heinrich B, Stemmer SM, Mala C, Kastner S, Bevan P Richters L, Schmalfeldt B, Harbeck N. A Randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). ASCO 2013 Oral presentation, J. Clin Oncol 31, suppl; Abstract 508.
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens. Clinical Breast Cancer, 14(6):396-404, 2014.
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ.: Risk of Positive Nonsentinel Nodes in Women with 1-2 Positive Sentinel Nodes Related to Age and Molecular Subtype Approximated by Receptor Status. Breast J Vol. 20(4) 358-363, July 2014. PubMed
Adams S, Gray RJ, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS.: Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014 Sept 20; 32(27):2959-67. PMID: 25513417.
Silverman, D, Ruth, KJ, Sigurdson, E, Egleston, BL, Goldstein, LJ, Boraas, M, Bleicher R.: Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal? Journal of the American College of Surgeons. Vol 219(3) 534-544 September 2014. PMCID: 4143438.
Matro J, Walia R, Tumelty K, Morrison T, Goldstein LJ.: Bilateral Hypoglossal Nerve Palsy Due to Breast Cancer Skull Base Metastases. AJHO Vol 10(5) 14-16, Nov. 2014.